Oric Pharmaceuticals Files Q1 2025 10-Q
Ticker: ORIC · Form: 10-Q · Filed: May 5, 2025 · CIK: 1796280
| Field | Detail |
|---|---|
| Company | Oric Pharmaceuticals, Inc. (ORIC) |
| Form Type | 10-Q |
| Filed Date | May 5, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financials
TL;DR
**ORIC Q1 10-Q FILED: Check financials & biz updates.**
AI Summary
Oric Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its business operations. Key financial data and disclosures related to its fiscal health and strategic initiatives are detailed within the filing.
Why It Matters
This filing provides investors with a quarterly update on Oric Pharmaceuticals' financial performance and operational status, crucial for assessing the company's trajectory in the competitive pharmaceutical sector.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Oric faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
- 2025-05-05 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
- 2024-01-01 to 2024-03-31 — Prior Year Q1 Period (Used for comparative financial analysis against the current reporting period.)
Key Players & Entities
- Oric Pharmaceuticals, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250505 (date) — Filing date
- 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO, CA 94080 (address) — Company's business and mail address
- Voronoi Inc. (company) — Mentioned in relation to milestones
FAQ
What is the primary business of Oric Pharmaceuticals, Inc.?
Oric Pharmaceuticals, Inc. is in the business of Pharmaceutical Preparations, as indicated by its SIC code [2834].
What is the fiscal year end for Oric Pharmaceuticals?
The fiscal year end for Oric Pharmaceuticals is December 31 (1231).
When was the Voronoi Inc. related milestone agreement initiated?
The filing references a milestone agreement with Voronoi Inc. on 2020-10-19.
What type of financial instruments are mentioned in relation to fair value measurements?
The filing mentions U.S. Treasury Securities and Money Market Funds in the context of recurring fair value measurements.
What is the company's primary business address?
The company's business address is 240 E. Grand Ave., 2nd Floor, South San Francisco, CA 94080.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 5, 2025 regarding Oric Pharmaceuticals, Inc. (ORIC).